AVR

Anteris Technologies Global Corp.
  • Healthcare
  • Medical - Devices
  • $812M market cap
Forecast run · Sep 14, 2026Upside rank 1076 of 3,136

Model Signal

ForecastQ Daily Probabilities
43.5%
35.9%
22.6%

Analyst Consensus

Recommendation2.00/5 Buy
Last price$8.35
Price target$18.00
Implied move+115.6%
Analysts2

ForecastQ Portfolios

AVR is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.

ForecastQ

Quantitative stocks signals powered by AI


The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.


© ForecastQ. All rights reserved.